<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000167" GROUP_ID="PREG" ID="446199081020101490" MERGED_FROM="" MODIFIED="2010-05-31 18:46:51 +0200" MODIFIED_BY="Sonja Henderson" NOTES="&lt;p&gt;Short title (no longer in use): Plasma volume expansion for impaired fetal growth&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-05-06 08:46:52 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0064" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2010-05-31 18:46:51 +0200" MODIFIED_BY="Sonja Henderson">
<TITLE>Plasma volume expansion for suspected impaired fetal growth</TITLE>
<CONTACT MODIFIED="2010-05-31 18:46:51 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-05-31 18:46:51 +0200" MODIFIED_BY="Sonja Henderson"><PERSON ID="13656" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lale</FIRST_NAME><LAST_NAME>Say</LAST_NAME><POSITION>Scientist, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP)</POSITION><EMAIL_1>sayl@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 7914816</PHONE_1><FAX_1>+ 41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15905" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A Metin</FIRST_NAME><LAST_NAME>Gülmezoglu</LAST_NAME><POSITION>Scientist</POSITION><EMAIL_1>gulmezoglum@who.int</EMAIL_1><URL>http://www.who.int/reproductive-health/rhl/index.html</URL><ADDRESS><DEPARTMENT>UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research</DEPARTMENT><ORGANISATION>World Health Organization</ORGANISATION><ADDRESS_1>20 Avenue Appia</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 7913417</PHONE_1><FAX_1>+41 22 7914171</FAX_1></ADDRESS></PERSON><PERSON ID="15917" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Justus</FIRST_NAME><LAST_NAME>Hofmeyr</LAST_NAME><POSITION>Director/Hon. Professor, Effective Care Research Unit</POSITION><EMAIL_1>gjh@global.co.za</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology, East London Hospital Complex</DEPARTMENT><ORGANISATION>University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health</ORGANISATION><ADDRESS_1>Frere and Cecilia Makiwane Hospitals</ADDRESS_1><ADDRESS_2>Private Bag X 9047</ADDRESS_2><CITY>East London</CITY><ZIP>5200</ZIP><REGION>Eastern Cape</REGION><COUNTRY CODE="ZA">South Africa</COUNTRY><PHONE_1>+27 43 7092483</PHONE_1><PHONE_2>+27 83 2809402</PHONE_2><FAX_1>+27 43 7092483</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-05-05 13:58:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/24/06&lt;/p&gt;&lt;p&gt;New studies sought but none found: 11/24/06&lt;/p&gt;&lt;p&gt;Reformatted: 8/12/99&lt;/p&gt;" NOTES_MODIFIED="2010-05-05 13:58:18 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="5" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="1996"/>
</DATES>
<WHATS_NEW MODIFIED="2010-04-23 14:50:38 +0100" MODIFIED_BY="Lynn Hampson" NOTES="&lt;p&gt;24 November 2006: search updated but no new trials identified.&lt;br&gt;30 June 2004: search updated but no new trials identified.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-04-23 14:50:38 +0100" NOTES_MODIFIED_BY="Lynn Hampson">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-04-23 14:50:38 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="23" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-04-23 14:50:14 +0100" MODIFIED_BY="Lynn Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-23 14:50:14 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="20" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-30 09:58:15 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-30 09:58:19 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="6" YEAR="2004"/>
<DESCRIPTION>
<P>Search updated but no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of the Witwatersrand</NAME>
<COUNTRY CODE="ZA">South Africa</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>HRP - UNDP/UNFPA/WHO/World Bank Special Programme in Human Reproduction, Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>UK Cochrane Centre, NHS R&amp;D Programme, Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-21 14:05:31 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-21 14:05:25 +0100" MODIFIED_BY="[Empty name]">Plasma volume expansion for suspected impaired fetal growth</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-21 14:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>Too little evidence to show whether it is beneficial for pregnant women to have extra plasma when the baby is growing more slowly than expected.</P>
<P>Plasma is the fluid that carries the blood cells in the body. The amount of plasma and blood cells (the blood) circulating in a woman's body can double during pregnancy. Sometimes, women whose babies are growing too slowly during pregnancy (impaired fetal growth) do not have as much blood circulating in their body as would be expected. Plasma volume expansion is where solutions are injected into the woman's bloodstream to increase plasma levels. No trials were found to show whether plasma volume expansion is beneficial for these women or their babies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-04-23 14:51:11 +0100" MODIFIED_BY="Lynn Hampson">
<ABS_BACKGROUND>
<P>Failure of the normal expansion of plasma volume in the mother is associated with impaired fetal growth and pre-eclampsia. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of plasma volume expansion for suspected impaired fetal growth.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-23 14:51:11 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2010).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized or quasi-randomized trials of plasma volume expansion compared to no plasma volume expansion in women with suspected impaired fetal growth.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Trial quality was assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No studies were included.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to evaluate the use of plasma volume expansion for suspected impaired fetal growth.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Impaired fetal growth is the failure of a newborn to achieve its genetically determined growth potential, which may cause death as well as short or long-term childhood morbidity. It has been reported that 3% to 10% of neonates are small for corresponding gestational age and an estimated 30% of this is due to impaired fetal growth. Remaining 70% is due to constitutional factors such as maternal ethnicity, parity, weight and height (<LINK REF="REF-Lin-1998" TYPE="REFERENCE">Lin 1998</LINK>). The condition occurs with limited flow of nutrients and/or oxygen from mother to fetus as a result of fetal causes (e.g. chromosomal abnormalities, congenital malformations), placental factors (e.g. small placenta), or maternal factors (e.g. malnutrition, vascular/renal disease, drugs or other metabolic conditions) (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). </P>
<P>Ultrasound evaluation of the fetus by measuring the abdominal circumference, head circumference, length of upper leg and interpreting these using standardised formulae allows the clinician to estimate the fetal weight, to relate this to the gestational age and to follow the growth progress. Ultrasound evaluation also allows to some extent to estimate the timing and the cause of the impairment. Symmetrical growth of the fetus is generally due to early problems such as chromosomal abnormalities, drugs, chemical agents or infection. Asymmetric growth usually results from inadequacy of substrates the fetus needs particularly later in pregnancy (<LINK REF="REF-Resnik-2002" TYPE="REFERENCE">Resnik 2002</LINK>). In low-income settings where early pregnancy ultrasound is not available fetal growth can be monitored by serial symphysis fundus measurements. However, there is no proven effective treatment that can be applied once growth impairment is diagnosed. In general, when no apparent congenital abnormality exists, management is conservative by frequent growth measurements, smoking cessation if the mother smokes and early delivery when the fetus is thought be mature enough to survive outside the womb. </P>
<P>The outcomes of impaired growth are variable and usually related to the specific cause. For example, if the growth impairment is due to chromosomal anomalies or congenital abnormalities, the fetus is more at risk of a perinatal death. Other short-term outcomes may be moderate to mild metabolic problems (hypoglycemia, polycythemia, meconium aspiration, etc.) due to the chronic oxygen and nutrient deprivation. Depending on the severity and the duration of the condition, long-term outcomes may differ from normal to small decreases in IQ to an increased risk of cerebral palsy (<LINK REF="REF-Bernstein-2000" TYPE="REFERENCE">Bernstein 2000</LINK>).</P>
<P>A significant increase in intravascular volume is a characteristic of normal pregnancy. Failure of this physiological plasma volume expansion is associated with increased incidence of impaired fetal growth and of pre-eclampsia. There is thus a rational basis for attempting to treat impaired fetal growth by therapeutic plasma volume expansion in the mother using substances with high osmotic pressure. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of plasma volume expansion for suspected impaired fetal growth.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All acceptably controlled evaluations of plasma volume expansion for suspected impaired fetal growth.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women with suspected or potential impaired fetal growth.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Plasma volume expansion to promote fetal growth.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-05-06 08:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>Fetal growth, birthweight, pregnancy duration, neonatal condition and complications, maternal complications.</P>
</CRIT_OUTCOMES_PRIMARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-04-23 14:51:49 +0100" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2010-04-23 14:51:49 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (March 2010). </P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>We did not apply any language restrictions.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Trials under consideration were evaluated for methodological quality and appropriateness for inclusion, without consideration of their results. Included trial data were processed as described in <LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-05-05 14:00:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-05-05 14:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>There are no randomized trials which fit the inclusion criteria. Three studies were excluded (<I>see</I> <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No trials included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Not applicable.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-05-05 14:00:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>See </I>
<LINK TAG="CONCLUSIONS" TYPE="SECTION">Authors' conclusions</LINK>.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is no evidence to support the routine use of plasma volume expansion in clinical practice for suspected impaired fetal growth.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Randomized trials with adequate design and sample sizes are needed to evaluate the possible advantages and risks of plasma volume expansion for suspected impaired fetal growth.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>None.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Justus Hofmeyr wrote the original review for the Cochrane Pregnancy and Childbirth Database. Metin Gülmezoglu updated the review, and has been responsible for maintaining the review since 1995. Both review authors did the data extraction and contributed to the text of the review. Lale Say contributed to the recent update by checking the data entries and revising the text of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bsteh-1995" NAME="Bsteh 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;10370&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bsteh M, Tews G, John D</AU>
<TI>Hemodilution in treatment of intrauterine dystrophy</TI>
<TO>Haemodilution bei der behandlung der intrauterinen dystrophie</TO>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1995</YR>
<VL>55</VL>
<PG>83-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heilmann-1991" NAME="Heilmann 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;[7089]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heilmann L, Lorch E, Hojnacki B, Muntefering H, Forster H</AU>
<TI>Accumulation of two different hydroxyethyl starch preparations in the placenta after hemodilution in patients with fetal intrauterine growth retardation or pregnancy hypertension</TI>
<SO>Infusionstherapie</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>236-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heilmann-1993" NAME="Heilmann 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;[8079]&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heilmann L, Tempelhoff G-Fv</AU>
<TI>Doppler sonographic results following hemodilution therapy</TI>
<SO>Zeitschrift fur Geburtshilfe und Perinatologie</SO>
<YR>1993</YR>
<VL>197</VL>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[10548]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tempelhoff G-Fv, Heilman L</AU>
<TI>The effect of plasma volume expansion on the uteroplacental perfusion</TI>
<SO>Clinical Hemorheology</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>729-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bernstein-2000" NAME="Bernstein 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A</AU>
<TI>Morbidity and mortality among very low birth weight infants with intrauterine growth restriction. The Vermont Oxford Network</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<PG>198</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1 [updated June 2000]</TI>
<SO>In: Review Manager (RevMan) [Computer program]. Version 4.1. Oxford, England: The Cochrane Collaboration, 2000</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lin-1998" NAME="Lin 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lin C, Santolaya-Forgas J</AU>
<TI>Current concepts of fetal growth restriction: Part 1. Causes, classification, and pathophysiology</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>6</NO>
<PG>1044-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnik-2002" NAME="Resnik 2002" TYPE="JOURNAL_ARTICLE">
<AU>Resnik R</AU>
<TI>Intrauterine growth restriction</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>99</VL>
<NO>3</NO>
<PG>490-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-05 14:01:08 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-05 14:01:08 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bsteh-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was excluded because all 20 pregnant women included in the study received haemodilution therapy with hydroxyethylstarch. 10 women were hospitalized while the other 10 were treated ambulatory.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-05 14:01:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heilmann-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-05 14:01:08 +0100" MODIFIED_BY="[Empty name]">
<P>73 women with suspected impaired fetal growth and/or gestational hypertension were "randomized" to receive plasma volume expansion with either hydroxyethylstarch 10% (group A, n = 37) or haemofusin (group B, n = 36). Haematological, placental histological and neonatal features were compared between 36 of group A and 24 of group B, and 102 non-randomized controls. There was no randomized comparison between treatment (hydroxyethylstarch) and control groups. The comparisons were made between 2 types of volume expanders (hydroxyethylstarch 10% versus haemofusin) and with 102 non-randomized controls. There were thus no comparisons between treated and randomly allocated control groups on the basis of which to evaluate the effectiveness of plasma volume expansion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heilmann-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data not available in a suitable form (Doppler). Small study (6 women in each group). The treatment was given for 14 days after enrolment.</P>
<P>12 women (6 in each group) with a high Hb (&gt; 13 g/dl), hematocrit (&gt; 38%) and fetal aorta resistance index (&gt; 0.75) underwent plasma volume expansion by 500 ml of hydroxyethylstarch (+ 500 ml of NaCl 0.9%) in a 'double- blind' fashion. The control group received 1000 ml of NaCl 0.9%. In both groups treatment continued for 14 days. The main outcome (Doppler resistance index) is not available in a suitable form for analysis. Plasma volume expansion caused a lowering of fetal aorta and uterine artery resistance index after 14 days. There was 1 case of intrauterine growth retardation in control group (diagnosed after delivery).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>